Cover Image
市場調查報告書

中國的紅血球生成素α市場分析

Investigation Report on China Epoetin Alfa Market, 2009-2018

出版商 China Research and Intelligence 商品編碼 297273
出版日期 內容資訊 英文 40 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
中國的紅血球生成素α市場分析 Investigation Report on China Epoetin Alfa Market, 2009-2018
出版日期: 2014年03月06日 內容資訊: 英文 40 Pages
簡介

紅血球生成素α是指促血紅細胞生長素(EPO),由腎臟、肝臟分泌的類似激素物質,有促進紅血球生成的作用。從1989年Amgen Inc.以「Epogen」的商品名得到美國FDA的認證以來,在全球40個國家以上上市。中國也因製造技術和價格下降、可支配所得上升為背景,EPO的市場成長,不過在農村還不十分普及。還有外科手術腫瘤治療的患者,多數由於EPO的化療還不十分普及,今後的潛在需求可說還很大。

本報告提供中國的紅血球生成素α的市場相關分析、中國國內的產量及醫院用銷售額、價格趨勢(過去5年份)、各企業、投藥形態的市場佔有率、未來性的市場趨勢預測(今後5年份)等調查,並將結果概述為以下內容。

第1章 紅血球生成素α的相關概念

  • 進展過程與症狀
  • 全球市場的銷售情形

第2章 中國的紅血球生成素α市場概要

  • 專利現況
  • 主要製造商
  • 市場規模

第3章 紅血球生成素α的銷售額分析

  • 整體銷售額
  • 各地區的銷售額

第4章 主要廠商的市場佔有率分析

  • 市場佔有率(以金額為準)
  • 市場佔有率(以數量為準)

第5章 各劑型的市場規模分析

  • 各劑型的市場佔有率(以金額為準)
  • 各劑型的市場佔有率(以數量為準)

第6章 紅血球生成素α的醫院用標準價格(各企業)

  • Shenyang Sunshine Pharmaceutical Co., Ltd.
  • 麒麟麥酒
  • NCPC GeneTech Biotechnology development Co., Ltd.
  • Beijing Sihuan Biopharmaceutical Co., Ltd.
  • Shanghai Chemo Wanbang Biopharmaceutical Co., Ltd.

第7章 主要製造商分析

  • Shenyang Sunshine Pharmaceutical Co., Ltd.
  • 麒麟麥酒
  • NCPC GeneTech Biotechnology development Co., Ltd.
  • Kyowa Hakko Kirin China Pharmaceutical Co., Ltd.
  • Beijing Sihuan Biopharmaceutical Co., Ltd.
  • Shanghai Chemo Wanbang Biopharmaceutical Co., Ltd.
  • Harbin Pharmaceutical Group Bio-Engineering Co., Ltd.
  • Shandong Kexing Bioproducts Co., Ltd.

第8章 中國的紅血球生成素α市場未來展望

  • 中國的貧血症、慢性腎臟病的發病率預測
  • 學名藥現況
  • 市場規模的預測
  • 市場模式的預測

圖表一覽

目錄
Product Code: 1403128

Epoetin alfa refers to erythropoietin (EPO), a hormone-like substance secreted by kidney and liver that stimulates erythropoiesis. Indications of EOP approved in China are renal anemia, anemia after chemotherapy and surgery perioperative red blood cell mobilization.

The ratio between EPO used in renal dialysis and in chemotherapy is 3:1. Growth rate of EPO used in chemotherapy is about 20% to 25%, which is higher than that of renal dialysis. However, in the international market, more EPO is used in anemia after chemotherapy than in renal dialysis. This indicates huge market space for EPO used in anemia after chemotherapy in China.

Originally developed by Amgen Inc., epoetin alfa was approved to the U.S. in June 1989 by FDA with the trade name "Epogen". It is sold in over 40 countries now. Amgen is the only authorized product sold in the U.S. hemodialysis market. However, in other indications' market in the U.S., due to financial shortage, Amgen gave the marketing right of Epogen to Kirin-Amgen, Inc. (joint venture of Amgen and Kirin). The company then authorized Ortho Pharmaceutical Corporation of Johnson & Johnson to sell the product with the brand name "Procrit". In other countries including Chinese mainland, Taiwan and Japan, the drug is sold by Kirin Inc. and Johnson & Johnson with the trade names "Espo" and "Eprex" respectively. Both the companies are authorized by Kirin-Amgen.

Domestic enterprises took more than half of Chinese EPO market, leading to a market dominated by domestic EPO. According to CRI's market investigation on Chinese sample hospital market, "Yi Bi Ao" produced by Shenyang Sunshine Pharmaceutical Co., Ltd. seizes more than half of the EPO market. Kirin Brewery takes more than 10% market share while the other is occupied by other Chinese manufacturers.

As manufacturing technique improves and cost declines as well as Chinese people's affordability increases, EPO is no longer as expensive as it was 10 years ago. However, due to expansion of communities and rural markets in China, more market space is provided for EPO to develop. The sales revenue of EPO in 2013 was more than CNY 1 billion in Chinese hospital market. Incidence of chronic kidney diseases among Chinese adults is over 10% with more than 140 million patients. The number continues to grow. If 1% of the patients eventually get end-stage renal disease, there will be over 1 million dialysis patients in China. In theory, if a renal dialysis patient uses one ampoule of EPO every 3 days, annual consumption of EPO injections in Chinese hospitals will be 100 million at least. In practice, however, most people cannot afford it. Half of Chinese population is from the rural, and they use significantly smaller amount of EPO compared with urban residents. Therefore less than half of the predicted amount of EPO is actually used. Consequently, the market is very promising.

In China, application of EPO in chemotherapy is far below a reasonable level, for tumor patients spend most of their money on antitumor surgeries and drugs before choosing EPO as the adjuvant drug. The EPO market is thus inevitably less developed than the antitumor drug market.

Annual sales revenue of EPO in China is under USD 300 million while that of the global market is USD 10 billion. On the one hand, consumption of EPO per capita in developed countries such as the U.S.A. is very large. On the other hand, renal dialysis is far from common enough in China. Among over 1 million patients who need renal dialysis merely 0.3 to 0.4 million patients are able to afford it. This has seriously hindered the popularization of EPO in China. As Chinese economy develops and health care improves, more patients will be able to afford renal dialysis. Estimation also shows that the development of renal dialysis market in China will significantly promote the development of EPO market.

Through this report, the readers can acquire the following information:

  • Demand of Epoetin Alfa in China Market
  • Market Share of Epoetin Alfa Produced by Different Enterprises in China Hospital Market
  • Sales Price of Epoetin Alfa in China Hospital Market
  • Major Epoetin Alfa Manufacturers in China
  • Market Overview of Epoetin Alfa in China

The following enterprises and people are recommended to purchase this report:

  • EPO APIs and Finished Product Manufacturers
  • Investors /Research Agencies Focusing on China EPO Drug Market

Table of Contents

1. Relevant Concepts of Epoetin Alfa

  • 1.1. Development Process and Indication
  • 1.2. Sales Status on the Global Market

2. Market Overview of Epoetin Alfa in China

  • 2.1. Patent Status
  • 2.2. Major Manufacturers
  • 2.3. Market Size

3. Investigation on Sales Value of Epoetin Alfa in China, 2009-2013

  • 3.1. Total Sales Value
  • 3.2. Sales Value by Region

4. Investigation on Market Share of Major Epoetin Alfa Manufacturers in China, 2009-2013

  • 4.1. Market Share by Sales Value
  • 4.2. Market Share by Sales Volume

5. Investigation on Market Size of Epoetin Alfa by Dosage Form in China, 2009-2013

  • 5.1. Market Share by Sales Value and Dosage Form
  • 5.2. Market Share by Sales Volume and Dosage Form

6. Reference Price of Epoetin Alfa Produced by Different Enterprises in China Hospital Market

  • 6.1. Shenyang Sunshine Pharmaceutical Co., Ltd.
  • 6.2. Kirin Brewery Company, Limited
  • 6.3. NCPC GeneTech Biotechnology development Co., Ltd.
  • 6.4. Beijing Sihuan Biopharmaceutical Co., Ltd.
  • 6.5. Shanghai Chemo Wanbang Biopharmaceutical Co., Ltd.

7. Analysis on Major Epoetin Alfa Manufacturers in China, 2009-2013

  • 7.1. Shenyang Sunshine Pharmaceutical Co., Ltd.
  • 7.2. Kirin Brewery Company, Limited
  • 7.3. NCPC GeneTech Biotechnology development Co., Ltd.
  • 7.4. Kyowa Hakko Kirin China Pharmaceutical Co., Ltd.
  • 7.5. Beijing Sihuan Biopharmaceutical Co., Ltd.
  • 7.6. Shanghai Chemo Wanbang Biopharmaceutical Co., Ltd.
  • 7.7. Harbin Pharmaceutical Group Bio-Engineering Co., Ltd.
  • 7.8. Shandong Kexing Bioproducts Co., Ltd.

8. Prospect of China Epoetin Alfa Market, 2014-2018

  • 8.1. Trend of Anemia and Chronic Kidney Disease Incidence in China
  • 8.2. Forecast on Market Size
  • 8.3. Forecast on Competition Pattern

Selected Charts

  • Chart Epoetin Alfa Products Approved to Market in China by 2014
  • Chart Sales Value of Epoetin Alfa in Global Market, 2009-2013
  • Chart Sales Value of Epoetin Alfa in China Hospital Market, 2009-2013
  • Chart Sales Value of Epoetin Alfa by Region in China, 2009-2013
  • Chart Market Share of Epoetin Alfa Enterprises by Sales Value in China, 2009-2013
  • Chart Price of Epoetin Alfa Produced by Boehringer Ingelheim in China Hospital Market, 2014
  • Chart Price of Epoetin Alfa Produced by Yichang Changjiang Pharmaceutical Co., Ltd. in China Hospital Market, 2014
  • Chart Forecast on Market Size of Hospital-use Epoetin Alfa in China, 2014-2018
Back to Top